Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | ACR | P10323 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 5/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925768 | 1.00 | MAPK1 (0.39) | MAPK1KMT2AKIF11NPSR1ACR | |
| SCHEMBL29696292 | 1.00 | MAPK1 (0.39) | MAPK1KMT2AKIF11NPSR1ACR | |
| SCHEMBL22925623 | 0.89 | ACR (0.40) | MAPK1KMT2AKIF11NPSR1ACR | |
| SCHEMBL28733616 | 0.89 | ACR (0.40) | MAPK1KMT2AKIF11NPSR1ACR | |
| SCHEMBL22925960 | 0.81 | CASP3 (0.42) | MAPK1KMT2AKIF11NPSR1CASP3 | |
| SCHEMBL28733790 | 0.81 | CASP3 (0.42) | MAPK1KMT2AKIF11NPSR1CASP3 | |
| SCHEMBL22925928 | 0.78 | KMT2A (0.40) | MAPK1KMT2AKIF11NPSR1KIT | |
| SCHEMBL28733637 | 0.78 | KMT2A (0.40) | MAPK1KMT2AKIF11NPSR1KIT | |
| SCHEMBL22925951 | 0.78 | MAPK1 (0.38) | MAPK1KMT2AKIF11NPSR1BACE1 | |
| SCHEMBL22925765 | 0.78 | MAPK1 (0.38) | MAPK1KMT2AKIF11NPSR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | MAPK1 567/4885KMT2A 3735/4885KIF11 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.